Nallasivam Palanisamy, MSc, MPhil, PhD (Genetics)

Associate Scientist
Department of Urology
Vattikutti Urology Institute, Henry Ford Health System
and
Associate Professor (Adjunct)
Michigan Center for Translational Pathology
Department of Pathology, University of Michigan, MI, USA

Biography

EDUCATION AND TRAINING

• (06/1979-06/1981) University of Madras, Chennai, India BSc, Zoology
• (06/1981-06/1983) University of Madras, Chennai, India MSc, Zoology
• (06/1983-06/1984) University of Madras, Chennai, India M.Phil. Human Genetics
• (05/1985-10/1993) University of Madras, Chennai, India PhD, Human Genetics
• (09/1990-05/1991) Postdoctoral Research Associate Molecular Biology, University of Vermont, Burlington, VT, USA
• (12/1993-04/1996) Postdoctoral Research Associate Molecular Biology Miami Childrens Hospital Research Institute, Miami, FL, USA
• (05/1996-11/1999) Postdoctoral Research Associate Cancer Cytogenetics/Molecular Cytogenetics Memorial Sloan-Kettering Cancer Center, New York City, NY, USA
• (07/2000-06/2002) American Board of Medical Genetics training program in Clinical Cytogenetics: Memorial Sloan–Kettering Cancer center, New York, NY
• (07/2001 42nd Annual course in Medical and experimental mammalian genetics, Jackson Laboratory co-organized with Johns Hopkins University, Bar Harbor, Maine, USA.- Course Director Victor A. McKusick
• (01/2009-03/2009) MBAEE-MBA Essentials and Entrepreneurship Michigan Ross School of Business University of Michigan, Ann Arbor, MI

ACADEMIC APPOINTMENTS

• (10/1991-11/1993) Cytogeneticist, Institute of Laboratory Sciences Kovai Medical Center and Hospital Ltd, Coimbatore, India
• (12/1999-03/2000) Senior Scientist, Research & Development Cancer Genetics Inc. Cambridge, MA, USA
• (04/2000-07/2004) Director, Research & Development Director, Genomics Research & Services Cancer Genetics Inc., Milford, MA, USA
• (08/2004-08/2007) Group Leader, Cancer Biology, Genome Institute of Singapore, Singapore
• (08/2005-08/2007) Adjunct Assistant Professor School of Biological Sciences Nanyang Technological University, Singapore
• (08/2007-08/2008) Consultant Molecular Cytogeneticist Genome Institute of Singapore, Singapore
• (08/2007-08/2012) Assistant Professor of Pathology Michigan Center for Translational Pathology Department of Pathology University of Michigan Medical School
• (09/2012-9/2014) Associate Professor of Pathology Michigan Center for Translational Pathology Department of Pathology University of Michigan Medical School University of Michigan, Ann Arbor, MI
• (10/2014-Present) Associate Scientist Vattikutti Urology Institute Department of Urology Henry Ford Health System Detroit, MI
• (03/2014-03/2015) Visiting Professor Department of Food and Nutrition Sciences King Saud University Riyadh, Saudi Arabia
• (01/2015-Present) Associate Professor (Adjunct) Michigan Center for Translational Pathology Department of Pathology University of Michigan Medical School University of Michigan, Ann Arbor, MI

Research Interest

His research interests include: Discovery and characterization of gene fusions in cancer and understand their role in carcinogenesis from a translational research perspective. Using genomic technologies such as high-density array comparative genomic hybridization, advanced molecular cytogenetic technologies including FISH, CGH, spectral karyotyping, gene expression microarrays, and next generation sequencing technology, his laboratory investigates the transcriptional and genomic architectures of solid cancer genome.

Scientific Activities

HONORS AND AWARDS

• (1983) First Prize for Merit in M.Sc., Zoology Kongunadu Arts and Science College, University of Madras
• (1985-1987) Junior Research Fellowships (JRF) Award
• (1987-1990) Senior Research Fellowship (SRF) Award, Council of Scientific and Industrial Research (CSIR), New Delhi, India
• (2000-2003) Small Business Innovative Research (SBIR) Grant awards, funded by National Cancer Institute, National Institutes of Health-NIH (Phase I: 3; Phase II: 1)
• (2006) Agilent Technologies University Relations Grant Award
• (2008) Best Reviewer Award- Singapore Medical Journal
• (2009) Melanoma Research Alliance Development Award
• (2009) Agilent Technologies University Relations Grant Award
• (2010-2012) University of Michigan Comprehensive Cancer Center Prostate Cancer SPORE-Career Development Award
• (2011) Whos Who in America-Marquis – 2011, 65th Edition (pub.2010)
• (2011) Recognition of Professional Development Award, University of Michigan, Department of Pathology REWARD-Employee Recognition Program
• (2013) Recognition of Professional Development Award, University of Michigan, Department of Pathology REWARD-Employee Recognition Program
• (2015) Member, Josephine Ford Cancer Institute (JFCI), Henry Ford Health System

MEMBERSHIP IN PROFESSIONAL SOCIETIES

• (1997-2004) Associate Member in American Society of Human Genetics (ASHG)
• (1997) Associate Member in American Association for Cancer Research (AACR)
• (2009-Present) Active Member in American Association for Cancer Research (AACR)

Publications

1. Lakshminarayana P, Nallasivam P. Cornelia de Lange syndrome with ring chromosome 3. J Med Genet. 1990; 27(6): 405-406.
2. Aikawa M, Sivam PN, Kuro-o M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993; 73(6): 1000-1012.
3. Iida S, Rao PH, Nallasivam P, et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996; 88(11): 4110-4117.
4. Selvakumar A, Steffens U, Palanisamy N, Chaganti RS, Dupont B. Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103. Tissue Antigens. 1997; 49(6): 564-573.
5. Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998; 58(19): 4260-4263.
6. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1998; 83(5): 1766-1770. doi: 10.1210/jcem.83.5.4806
7. Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE. A common molecular basis for rearrangement disorders on chromosome 22q11. Hum Mol Genet. 1999; 8(7): 1157-1167.
8. Brown SB, Brierley TT, Palanisamy N, et al. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab. 2000; 85(2): 868-872.
9. Dyomin VG, Palanisamy N, Lloyd KO, et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood. 2000; 95(8): 2666-2671.
10. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001; 14(3): 277-289. doi: 10.1016/S1074-7613(01)00109-1
11. Chen W, Palanisamy N, Schmidt H, et al. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene. 2001; 20(52): 7686-7693.
12. Butler MP, Iida S, Capello D, et al. Alternative translocation breakpoint cluster region 5 to BCL-6 in B-cell non-Hodgkins lymphoma. Cancer Res. 2002; 62(14): 4089-4094.
13. Palanisamy N, Abou-Elella AA, Chaganti SR, et al. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer. 2002; 33(2): 114-122. doi: 10.1002/gcc.10016
14. Dyomin VG, Chaganti SR, Dyomina K, et al. BCL8 is a novel, evolutionarily conserved human gene family encoding proteins with presumptive protein kinase A anchoring function. Genomics. 2002; 80(2): 158-165. doi: 10.1006/geno.2002.6822
15. Imanishi Y, Tahara H, Palanisamy N, et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002; 13(6): 1490-1498. doi: 10.1097/01.ASN.0000018148.50109.C0
16. Costa J, Shattuck TM, Imanishi Y, et al. Mutational analyses of connexin 26, connexin 30 and connexin 46 as candidate tumor suppressor genes in parathyroid carcinoma. J Endocr Genet. 2002; 3: 57-62.
17. Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf). 2003; 59(2): 180-189.
18.Houldsworth J, Olshen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2004; 103(5): 1862-1868.
19. Schmidt HH, Dyomin VG, Palanisamy N, et al. Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32). Oncogene. 2004; 23(41): 6991-6996.
20. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol. 2005; 166(4):1229-1238.
21.Lian Q, Lye E, Suan Yeo K, et al. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells. 2007; 25(2): 425-436.
22.Chen W, Salto-Tellez M, Palanisamy N, et al. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer. 2007; 46(3): 288-301. doi: 10.1002/gcc.20411
23. Ruan Y, Ooi HS, Choo SW, et al. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res. 2007; 17(6): 828-838. doi: 10.1101/gr.6018607
24. Lin CY, Vega VB, Thomsen JS, et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 2007; 3(6): e87.
25. Zeng J, Du J, Zhao Y, Palanisamy N, Wang S. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells. 2007; 25(4): 1055-1061. doi: 10.1634/stemcells.2006-0616
26. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008; 68(18): 7629-7637. doi: 10.1158/0008-5472.CAN-08-2014
27. Poonepalli A, Banerjee B, Ramnarayanan K, Palanisamy N, Putti TC, Hande MP. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. Genes Chromosomes Cancer. 2008; 47(12): 1098-1109.
28. Legrand B, Chang CS, Ong SH, Neo SY, Palanisamy N. Automated identification of chromosome segments involved in translocations by combining spectral karyotyping and banding analysis. IEEE Transactions on Systems, Man & Cybernetics (Part A Systems & Humans). 2008; 38(6): 1374-1384.
29. Huynh H, Chow PK, Palanisamy N, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008; 49(1): 52-60.
30. Legrand B, Chang CS, Ong SH, Neo S-Y, Palanisamy N. Chromosome Classification Using Dynamic Time Warping. Pattern Recognition Letters. 2008; 29: 215-222.
31.Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908): 1695-1699.
32. Zhang J, Liu X, Datta A, et al. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009; 119(8): 2171-2183. doi: 10.1172/JCI37622
33. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009; 22(9): 1176-1185. doi: 10.1038/modpathol.2009.79
34. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22(8): 1083-1093.
35. Wang XS, Prensner JR, Chen G, et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009; 27(11): 1005-1011. doi: 10.1038/nbt.1584
36. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009; 458(7234): 97-101. doi: 10.1038/nature07638
37. Vega VB, Cheung E, Palanisamy N, Sung WK. Inherent signals in sequencing-based Chromatin-ImmunoPrecipitation control libraries. PLoS One. 2009; 4(4): e5241.
38. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009; 326(5957): 1230. doi: 10.1126/science.1178124
39. Maher CA, Palanisamy N, Brenner JC, et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA. 2009; 106(30): 12353-12358. doi: 10.1073/pnas.0904720106
40. Palanisamy N. Chromosomal translocations in AML: detection and prognostic significance. Cancer Treat Res. 2010; 145: 41-58. doi: 10.1007/978-0-387-69259-3_3
41.Han B, Suleman K, Wang L, et al. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010; 34(4): 478-485. doi: 10.1097/PAS.0b013e3181d6827b
. 42.Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010; 16(7): 793-798. doi: 10.1038/nm.2166
43. Chandra N, Cyril C, Lakshminarayana P, et al. Cytogenetic Evaluation of Down syndrome: A Review of 1020 Referral Cases. Int J Hum Genet. 2010; 10(1-3): 87-93.
44. Yu J, Cao Q, Yu J, et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 2010; 29(39): 5370-5380.
45. Chinnaiyan AM, Palanisamy N. Chromosomal aberrations in solid tumors. Prog Mol Biol Transl Sci. 2010; 95: 55-94.
46. Wang J, Cai Y, Shao LJ, et al. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res. 2011; 71(4): 1325-1333.
47. Wang XS, Shankar S, Dhanasekaran SM, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov. 2011; 1(1): 35-43.
48. Oh HK, Tan AL, Das K, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011; 17(9): 2657-2667. doi: 10.1158/1078-0432.CCR-10-3152.
49. Banerjee R, Mani RS, Russo N, et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011; 30(42): 4339-4349.
50. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011; 19(5): 664-678. doi: 10.1016/j.ccr.2011.04.010
51.Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011; 29(8): 742-749. doi: 10.1038/nbt.1914
52. Tao J, Deng NT, Ramnarayanan K, et al. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011; 3(77):77ra30.
53. Kim JH, Dhanasekaran SM, Prensner JR, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011; 21(7): 1028-1041. doi: 10.1101/gr.119347.110.
54.Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011; 3(94): 94ra72. doi: 10.1126/scitranslmed.3001970
55. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 2011; 32(11): 1607-1614.
56. Cao Q, Mani RS, Ateeq B, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011; 20(2): 187-199. doi: 10.1016/j.ccr.2011.06.016.
57. Robinson DR, Kalyana-Sundaram S, Wu YM, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011; 17(12): 1646-1651. doi: 10.1038/nm.2580
58. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012; 136(8): 935-946.
59.Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406): 239-243.
60. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012; 149(7): 1622-1634
. 61.Young A, Palanisamy N, Siddiqui J, et al. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol. 2012; 138(5): 685-696. doi: 10.1309/AJCPU7PPWUPYG8OH.
62.Kalyana-Sundaram S, Shankar S, Deroo S, et al. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia. 2012; 14(8): 702-708.
63.Wang R, Asangani IA, Chakravarthi BV, et al. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia. 2012; 14(10): 905-914.
64. Asangani IA, Harms PW, Dodson L, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012; 3(9): 1011-1025.
65. Asangani IA, Ateeq B, Cao Q, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2013; 49(1): 80-93.
66. Bhalla R, Kunju LP, Tomlins SA, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013; 26(6): 835-848. doi: 10.1038/modpathol.2012.234
67. Velusamy T, Palanisamy N, Kalyana-Sundaram S, et al. Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2013; 110(8): 3035-3040.
68. Ithimakin S, Day KC, Malik F, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013; 73(5): 1635-1646. doi: 10.1158/0008-5472.CAN-12-3349
69.Tomlins SA, Palanisamy N, Brenner JC, et al. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol. 2013; 139(6): 771-779.
70.Costa-Guda J, Imanishi Y, Palanisamy N, et al. Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. 2013; 44(2): 489-495. doi: 10.1007/s12020-013-9903-4
71.Mehra R, Dhanasekaran SM, Palanisamy N, et al. Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Transl Oncol. 2013; 6(4): 405-412.
72.Smith SC, Palanisamy N, Zuhlke KA, et al. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol. 2014; 38(5): 615-626.
73.Warrick JI, Tomlins SA, Carskadon SL, et al. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization–a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol. 2014; 27(4): 609-620. doi: 10.1038/modpathol.2013.169
74.Smith SC, Palanisamy N, Betz BL, et al. At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases. Histopathology. 2014; 65(1): 144-146. doi: 10.1111/his.12354.
75. Sathyanarayana UG, Birch C, Nagle RB, et al. Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis. Appl Immunohistochem Mol Morphol. 2014.
76. Kunju LP, Carskadon S, Siddiqui J, Tomlins SA, Chinnaiyan AM, Palanisamy N. Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol. 2014; 22(8): e32-e40.
77. Zuhlke KA, Johnson AM, Tomlins SA, et al. Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate. 2014; 74(9): 983-990.
78. Banerjee R, Russo N, Liu M, et al. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014; 5: 4527.
79. Pletneva MA, Andea A, Palanisamy N, et al. Clear cell melanoma: a cutaneous clear cell malignancy. Arch Pathol Lab Med. 2014; 138(10): 1328-1336.
80. Chakravarthi BV, Pathi SS, Goswami MT, et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014; 5(16): 6654-6669.
81. Harms PW, Hristov AC, Kim DS, et al. Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. Human Pathology- #Case Reports. 2014; 1(2): 21-28.
82.Palanisamy N, Tsodikov A, Yan W, et al. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. Urol Oncol. 2014.
83. Wan X, Corn PG, Yang J, et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014; 6(252): 252ra122.
84. Ha Lan TT, Chen SJ, Arps DP et al. Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. J Cutan Pathol. 2014; 41(11): 831-838. doi: 10.1111/cup.12387
85. Harms PW, Fullen DR, Patel RM, et al.Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. Hum Pathol. 2015.
86.Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014; 5: 5383.
87. Fisher CA, Harms PW, McHugh JB, et al. Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118(6): 703-712. doi: 10.1016/j.oooo.2014.09.012
88.Dhanasekaran SM, Alejandro Balbin O, Chen G, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014; 5: 5893. doi: 10.1038/ncomms6893
89.Higgins J, Brogley M, Palanisamy N, et al. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015.
90. Ateeq B, Kunju LP, Carskadon SL, et al. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. Prostate. 2015.
91. Malik R, Khan AP, Asangani IA, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015.
92. Bollig-Fischer A, Michelhaugh SK, Wijesinghe P, et al. Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget. 2015. 93. Demicco EG, Harms PW, Patel RM, et al. Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. Am J Clin Pathol. 2015; 143(5): 672-682. doi: 10.1309/AJCPN25NJTOUNPNF
94. Palanisamy N. Hopes and pitfalls in prostate cancer diagnostics and therapeutics. Journal of Rashid Latif Medical College. 2014; 3(2).
95. Goswami MT, Chen G, Chakravarthi BV, et al. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015.